Trials / Terminated
TerminatedNCT04638634
Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects
A Single Center, Phase 1, Single-Ascending Dose, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- CSL Behring · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
CSL760 is a human hyperimmune product of the purified gamma immunoglobulin (IgG) fraction of human plasma containing polyvalent neutralizing antibodies to SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2). CSL is evaluating CSL760 as a passive immunotherapy for COVID-19 (Coronavirus Disease 2019).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CSL760 | An Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin |
Timeline
- Start date
- 2021-02-02
- Primary completion
- 2021-06-09
- Completion
- 2021-06-09
- First posted
- 2020-11-20
- Last updated
- 2021-12-10
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT04638634. Inclusion in this directory is not an endorsement.